Diana Kaya

Diana Kaya

Auto-generated profile, based on publicly available information

Diana Kaya

From the Department of Neuroradiology (R.D., H.A.Q., D.K., S.A., M.W.) and Department of Imaging Physics (P.S., B.A.T., P.H., H.-L.L.), The University of Texas MD Anderson Cancer Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2021 in Neurology
Verified
Journal Article
Closed access
PDF file
Ashley AaroeAshley Aaroe
Ashley Aaroe
IOIsabella Glitza Oliva
Isabella Glitza Oliva
Nagham Al-ZubidiNagham Al-Zubidi
Nagham Al-Zubidi
MNMarc-Elie Nader
Marc-Elie Nader
DKDiana Kaya
Diana Kaya
RHRebecca Harrison
Rebecca Harrison

11 February 2026 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
RDRichard Dagher
Richard Dagher
PSPeng Sun
Peng Sun
HQHeba Al Qudah
Heba Al Qudah
DKDiana Kaya
Diana Kaya
SASahar Alizada
Sahar Alizada
Ho-Ling LiuHo-Ling Liu
Ho-Ling Liu
Dynamic susceptibility contrast (DSC) MRI is widely used to assess relative cerebral blood volume (rCBV) in brain tumors using gadolinium-based contrast agents. Gadopiclenol, recently FDA-approved for use at half dose due to its high relaxivity, offers a potential strategy to reduce overall gadolinium exposure. This retrospective study evaluated DSC MRI performance with 0.05 mmol/kg gadopiclenol compared with standard-dose (0.10 mmol/kg) gadobutrol. 20 patients with brain tumors underwent gadopiclenol-based DSC MRI on 3T scanners and were compared with 20 matched controls receiving gadobutrol. Analysis of normal-appearing thalamic, frontal cortical gray matter, and white matter regions showed that gadopiclenol produced DSC time curves with shapes similar to gadobutrol, though with significantly smaller signal decreases and approximately half the peak ΔR2* values, consistent with dose scaling. Importantly, normalized rCBV values did not differ significantly between contrast agents in gray matter regions. These findings support the use of half-dose gadopiclenol for reliable rCBV assessment while reducing gadolinium exposure.

12 December 2024 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
RERami W. Eldaya
Rami W. Eldaya
DKDiana Kaya
Diana Kaya
MWMichelle Williams
Michelle Williams
SCSusana Calle
Susana Calle
DSDawid Schellingerhout
Dawid Schellingerhout
SUMMARY: High-grade gliomas are the most frequent primary brain tumors, yet extraneural metastasis is exceedingly rare. This is in part secondary to the relatively poor survival of these patients and likely the shielding effect of the blood-brain barrier. Given the rarity of extraneural metastasis, the pathophysiology and imaging appearance of extraneural metastasis is under-reported and poorly understood. In this case series we present 6 patients with pathology-confirmed high-grade glioma and extraneural head and neck metastasis. We highlight imaging features of metastasis on CT, MRI, and PET/CT. We also explore potential correlations and pathophysiology of high-grade glioma metastasis to the head and neck region.

29 April 2020
Verified
Conference Paper
Open access
DKDiana Kaya
Diana Kaya
Imaging Findings of Distinct Molecular Subgroups of Medulloblastoma: All Fingers of the Palm are not the Same Purpose: WHO 2016 classification of brain tumors integrates 4 molecular defined subgroups of medulloblastoma: Wingless (WNT-activated), Sonic Hedgehog (SHH-activated) and TP53-mutant; Group 3 and Group 4. Each subgroup is characterized by specific molecular features, age